ABCL Logo

AbCellera Biologics Inc. (ABCL) 

NASDAQ
Market Cap
$841.79M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
165 of 960
Rank in Industry
112 of 550

Largest Insider Buys in Sector

ABCL Stock Price History Chart

ABCL Stock Performance

About AbCellera Biologics Inc.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is …

Insider Activity of AbCellera Biologics Inc.

Over the last 12 months, insiders at AbCellera Biologics Inc. have bought $739,977 and sold $0 worth of AbCellera Biologics Inc. stock.

On average, over the past 5 years, insiders at AbCellera Biologics Inc. have bought $30.04M and sold $394.03M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Thermopylae Holdings Ltd. (10 percent owner) — $739,977.

The last purchase of 283,516 shares for transaction amount of $739,977 was made by Thermopylae Holdings Ltd. (10 percent owner) on 2024‑08‑29.

List of Insider Buy and Sell Transactions, AbCellera Biologics Inc.

2024-08-29Purchase10 percent owner
283,516
0.0993%
$2.61$739,977+7.91%
2023-11-08Purchasedirector
10,000
0.0037%
$4.46$44,600-3.75%
2023-11-06Purchasedirector
20,000
0.0071%
$4.64$92,800-9.70%
2023-09-22Purchasedirector
20,000
0.0066%
$4.91$98,200-12.40%
2023-09-12PurchaseChief Operating Officer
20,000
0.007%
$5.19$103,800-14.30%
2023-08-08Purchasedirector
30,000
0.0104%
$5.90$177,000-22.03%
2023-05-26Purchase10 percent owner
153,000
0.051%
$6.52$997,728-26.32%
2023-05-26PurchaseChief Financial Officer
14,500
0.0051%
$6.85$99,325-26.32%
2022-12-16Purchasedirector
85,102
0.0295%
$10.10$859,249-33.50%
2022-08-19Purchase10 percent owner
200,000
0.0702%
$11.46$2.29M-19.58%
2022-06-14Purchase10 percent owner
9,173
0.0029%
$8.05$73,842+16.48%
2022-06-13Purchase10 percent owner
54,915
0.0189%
$8.03$441,066+25.00%
2022-06-06Purchase10 percent owner
64,545
0.0222%
$7.50$483,965+33.64%
2022-05-16PurchaseChief Operating Officer
200,000
0.057%
$6.34$1.27M+31.24%
2022-05-13Purchase10 percent owner
300,000
0.1057%
$7.26$2.18M+41.77%
2022-05-12Purchase10 percent owner
1.41M
0.4723%
$6.41$9.02M+52.76%
2022-05-12PurchaseChief Financial Officer
85,000
0.0258%
$5.79$492,150+52.76%
2022-03-04Purchasedirector
10,000
0.0035%
$8.54$85,400+20.22%
2022-03-01Purchasedirector
20,000
0.0071%
$9.05$181,000+13.38%
2022-02-28PurchaseChief Operating Officer
230,789
0.0808%
$8.66$2M+17.68%

Insider Historical Profitability

<0.0001%
Thermopylae Holdings Ltd.10 percent owner
56086009
18.9886%
$2.85101+6.49%
THIEL PETERdirector
10179880
3.4465%
$2.8510<0.0001%
Lecault VeroniqueChief Operating Officer
2040122
0.6907%
$2.8541<0.0001%
Hayden Michael Rdirector
1323397
0.4481%
$2.8531<0.0001%
Booth AndrewChief Financial Officer
153000
0.0518%
$2.8531<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Baker Bros Advisors LP$124.69M9.3627.53M+20.15%+$20.91M0.9
Baillie Gifford Co$105.01M7.8823.18M-3.6%-$3.92M0.08
Voya Investment Management LLC$48.16M3.6210.63M+0.07%+$36,008.970.05
Capital World Investors$37.83M2.848.35M0%+$00.01
Credit Suisse$20.6M1.554.55M-0.68%-$140,135.550.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.